Angion Biomedica Company

Angion is a clinical stage biopharmaceutical company focused on acute kidney injury, a potentially life-threatening condition without therapeutic options. Our lead clinical asset, ANG-3777, is engineered to activate the HGF/c-MET pathway, an…
Technology: Data-driven Technologies
Industry: Small&Large Molecules
Headquarters: New York, United States
Founded Date: 1998
Employees Number: 11-50
Funding Status: IPO
Investors Number: 2
Total Funding: 44356452
Estimated Revenue: $10M to $50M
Last Funding Date: 2021
Last Funding Type: Post-IPO Equity

Visit Website
mail@angion.com
Register and Claim Ownership